The Consistency and Transferability of Economic Evaluations of Disease-Modifying Treatments for Multiple Sclerosis: Analysis of Cost-Effectiveness Assessments from Australia, England, Canada and Scotland.
Xiang Wang, Feili Zhao, David Newby, Lan Gao, Shuchuen Li
{"title":"The Consistency and Transferability of Economic Evaluations of Disease-Modifying Treatments for Multiple Sclerosis: Analysis of Cost-Effectiveness Assessments from Australia, England, Canada and Scotland.","authors":"Xiang Wang, Feili Zhao, David Newby, Lan Gao, Shuchuen Li","doi":"10.1007/s41669-025-00606-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Our study examines the consistency and transferability of cost-effectiveness values, specifically the incremental cost-effectiveness ratio (ICER), focusing on several disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS) approved by four of the most established Health Technology Assessment (HTA) bodies.</p><p><strong>Methods: </strong>Data of economic evaluation results for DMTs were extracted from the HTA reports published by four agencies. Descriptive statistics were employed to identify correlations between the accepted ICERs within and across agencies. Two different currency conversion approaches were employed to investigate the feasibility and efficiency for transferring accepted ICERs across jurisdictions.</p><p><strong>Results: </strong>The study analysed ten DMTs that received positive recommendations from four agencies: the National Institute for Health and Care Excellence (NICE), Scottish Medicines Consortium (SMC), Pharmaceutical Benefits Advisory Committee (PBAC) and Canada's Drug Agency (CDA). The consistency of accepted ICER values for the class of DMTs was observed within the four agencies; however, the commonality of accepted ICER values was only observed between some agencies, such as the CDA and NICE, as well as the PBAC and SMC. Purchasing power parity-adjusted ICER values were found to provide better transference of ICER outcomes as compared to the exchange-rate method.</p><p><strong>Conclusion: </strong>This study highlighted the consistency of the economic evaluation for DMTs within the four agencies. We also identified a particularly strong alignment between NICE and the CDA, as well as the PBAC and SMC. Additionally, the examination of two ICER value conversion methods pinpointed key factors that could impact the transference of ICER values.</p>","PeriodicalId":19770,"journal":{"name":"PharmacoEconomics Open","volume":" ","pages":"97-108"},"PeriodicalIF":2.4000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12796072/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PharmacoEconomics Open","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s41669-025-00606-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/10/23 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ECONOMICS","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Our study examines the consistency and transferability of cost-effectiveness values, specifically the incremental cost-effectiveness ratio (ICER), focusing on several disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS) approved by four of the most established Health Technology Assessment (HTA) bodies.
Methods: Data of economic evaluation results for DMTs were extracted from the HTA reports published by four agencies. Descriptive statistics were employed to identify correlations between the accepted ICERs within and across agencies. Two different currency conversion approaches were employed to investigate the feasibility and efficiency for transferring accepted ICERs across jurisdictions.
Results: The study analysed ten DMTs that received positive recommendations from four agencies: the National Institute for Health and Care Excellence (NICE), Scottish Medicines Consortium (SMC), Pharmaceutical Benefits Advisory Committee (PBAC) and Canada's Drug Agency (CDA). The consistency of accepted ICER values for the class of DMTs was observed within the four agencies; however, the commonality of accepted ICER values was only observed between some agencies, such as the CDA and NICE, as well as the PBAC and SMC. Purchasing power parity-adjusted ICER values were found to provide better transference of ICER outcomes as compared to the exchange-rate method.
Conclusion: This study highlighted the consistency of the economic evaluation for DMTs within the four agencies. We also identified a particularly strong alignment between NICE and the CDA, as well as the PBAC and SMC. Additionally, the examination of two ICER value conversion methods pinpointed key factors that could impact the transference of ICER values.
期刊介绍：
PharmacoEconomics - Open focuses on applied research on the economic implications and health outcomes associated with drugs, devices and other healthcare interventions. The journal includes, but is not limited to, the following research areas:Economic analysis of healthcare interventionsHealth outcomes researchCost-of-illness studiesQuality-of-life studiesAdditional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in PharmacoEconomics -Open may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand important medical advances.All manuscripts are subject to peer review by international experts. Letters to the Editor are welcomed and will be considered for publication.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
